LBRX
LB Pharmaceuticals Inc
44.71
-0.23 (-0.51%)
52w low 14.40
50.16 high
84.8% of range
Financial Analysis
| (USD) | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 14.22M | 269.74M | 250.17M | 320.68M | 283.11M | |
| Current Assets | 14.78M | 316.40M | 308.43M | 389.07M | 355.30M | |
| Net PP&E | 3.96M | 3.83M | 3.73M | 3.63M | 5.61M | |
| Total Assets | 19.25M | 320.75M | 312.93M | 393.48M | 361.69M | |
| Current Liabilities | 3.91M | 6.65M | 7.44M | 10.91M | 23.56M | |
| Total Debt | 3.76M | 3.67M | 3.57M | 3.47M | 5.22M | |
| Total Liabilities | 123.12M | 10.53M | 11.62M | 14.79M | 29.34M | |
| Retained Earnings | -114.50M | -118.06M | -129.53M | -148.58M | -200.19M | |
| Shareholders Equity | -103.87M | 310.22M | 301.31M | 378.69M | 332.35M | |
| Working Capital | 10.88M | 309.75M | 300.99M | 378.17M | 331.74M | |
| Shares Outstanding | 22.44M | 25.30M | 25.30M | 28.67M | 28.68M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--